The time for re-thinking patient adherence is now.

There is growing recognition that patient non-adherence to prescribed treatment is a major public health issue. In the US, it is estimated that complications and additional care needed by non-adherent patients cause $310 billion of unnecessary costs to the healthcare industry each year.

For pharmaceutical companies, improvement in patient adherence represents a significant revenue opportunity. In this report, we analyze the current state of patient adherence and the challenges and key success factors involved in improving it.